PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2026Journal of Clinical Oncology1 citations

Efficacy and Safety of Lunbotinib in RET Fusion-Positive Non-Small Cell Lung Cancer

Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).

View Full Paper
Ask AI
Bookmark
Share

Authors

QZQ ZhouYWYan WuXLXingYa Li

Discussion

Loading...

Member takes

Overview

Randomized trial shows robust efficacy of lunbotinib in RET fusion-positive non-small cell lung cancer, indicating its potential as a treatment option.

Key Points

  • The aim is to evaluate the efficacy and safety of lunbotinib in patients with advanced RET fusion-positive non-small cell lung cancer.
  • Phase II study design with two single-arm cohorts: pre-treated and treatment-naïve patients.
  • Patients received oral lunbotinib 90 mg daily in 28-day cycles until progression or unacceptable toxicity.
  • Primary endpoint assessed was Objective Response Rate (ORR) by an independent review committee.
  • In pre-treated patients, the confirmed ORR was 87.1% (95% CI: 77.0-93.9) and mPFS was 27.5 months.
  • Treatment-naïve patients demonstrated an ORR of 81.3% (95% CI: 71.8-88.7) and an NR for mPFS.
  • Treatment-related adverse events occurred in 98.8% of patients, with manageable safety.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/6a192e79fab5b468c44179e0https://doi.org/10.1200/jco.2026.44.16_suppl.8505
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC2026
  2. 2Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced<i> RET</i>-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study.2024 · 4 citations
  3. 3Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.2026
  4. 4A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.2024 · 2 citations
  5. 5Efficacy and safety of pralsetinib as first-line treatment of <i>RET</i> fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.2026